Testosterone Therapy and Prostate Health: Examining Barriers to Treatment of Hypogonadism CME Certificate Registration and Pretest

CME credit is offered upon successful completion of the Posttest with a minimum score of 70% and submission of the Evaluation after the activity.


QUICK REGISTRATION (TU MEMBERS)

If you are already a member of TestosteroneUpdate®, just enter your username and password below to autofill the registration form. Want to become a member? Click here

(case-sensitive)




FULL REGISTRATION (NON-TU MEMBERS)

Please complete the form below to register for this activity. Your CME certificate will be issued from the following information.

* indicates a required field

Endocrinology  Family medicine  Internal medicine  Primary Care  Urology
Other (please specify)
Clinic                   Home care           Hospital-based         Long-term care
Private practice     University-based  Other (please specify)
Business Personal
(Used for record-keeping purposes only)
Because you have attended or shown interest in our programs, we may send you information on this and similar programs utilizing the e-mail address provided. You may unsubscribe at any time by clicking on the “unsubscribe” link on any e-mails received from us.

Please do not send me information via e-mail.

Privacy Policy
We value the confidentiality of the information you choose to share with us and are committed to its protection. All personal information you provide is stored in a secure location and will never be sold or distributed to any third party.



PRETEST
Select the best answer to each question. All fields are required.

1. 

Normalizing serum androgen levels with testosterone therapy appears to ______ prostate-tissue androgen levels and androgen-dependent cellular functions.
 Have a significant effect on
 Have little effect on
 Increase
 Decrease

2. 

Although preliminary results of recent studies suggest that normalizing testosterone levels in older men may positively affect International Prostate Symptom Score (IPSS) and there is a lack of evidence supporting a causal relationship between exogenous testosterone and prostate cancer, the prescribing information for every testosterone therapy reinforces the need to ______.
 Monitor patients with benign prostatic hyperplasia (BPH) for worsening of signs and symptoms of BPH
 Evaluate patients for prostate cancer before initiating testosterone therapy and monitor during testosterone therapy
 Monitor patients with BPH for worsening of signs and symptoms of BPH, evaluate patients for prostate cancer before initiating testosterone therapy, and monitor during testosterone therapy
 None of the above

3. 

A 57-year-old patient who is concerned about maintaining his sexual function has been receiving daily phosphodiesterase type 5 (PDE5) inhibitor therapy for the treatment of comorbid erectile dysfunction (ED; Sexual Health Inventory for Men [SHIM] score, 8 [moderate ED]) and BPH/lower urinary tract symptoms (LUTS; American Urological Association Symptom Index [AUA-SI] score, 12 [moderate LUTS]). During his recent follow-up, the patient reveals low energy, worsening erectile function, and diminished libido, and laboratory findings indicate hypogonadism (serum total testosterone, 190 ng/dL). Which of the following statements is correct?
 Treatment with testosterone therapy may be appropriate, based on signs and symptoms and serum evaluation
 Treatment with testosterone therapy is contraindicated, based on the AUA-SI score
 The patient should be switched to α-blocker therapy
 Combination therapy with a PDE5 inhibitor plus tamsulosin should be initiated

4. 

The Saturation Model suggests that ______.
 The relationship of testosterone to prostate cancer growth is that of "fuel for a fire"
 Prostate cancer growth is exquisitely sensitive to variations in androgen levels at very low concentrations but becomes insensitive to such variations at high concentrations
 Prostate cancer growth is exquisitely sensitive to variations in androgen levels at very high concentrations but becomes insensitive to such variations at low concentrations
 Prostate cancer growth is exquisitely sensitive to variations in androgen levels at any concentration

5. 

Approximately what percentage of your patients presenting with BPH/LUTS do you screen for hypogonadism?
 0% to 25%
 26% to 50%
 51% to 75%
 76% to 100%


   




© 2012 CogniMed Inc. All rights reserved.            TU14139/ACHS 4972             August 2012